General Information of the Compound
Compound ID |
CP0041221
|
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Compound Name |
1-(5-Oxohexyl)theobromine (pentoxifylline)
Show/Hide
|
||||||||||||||||||
Synonyms |
1,2,3,6-Tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion
1-(5-Oxohexyl)-3,7-dimethylxanthine
1-(5-Oxohexyl)theobromine
3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione
3,7-Dimethyl-1-(5-oxo-hexyl)-3,7-dihydro-purine-2,6-dione
3,7-Dimethyl-1-(5-oxohexyl) xantine
3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione
3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione
3,7-Dimethyl-1-(5-oxohexyl)xanthine
3,7-Dimethyl-1-(5-oxohexyl)xantine
3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
Agapurin
Agapurin Retard
Artal (TN)
Azupentat
BL 191
BL-191
BL191
Cis-9-Octadecenoyl coenzyme A
Dimethyloxohexylxanthine
Durapental
EHT 0201
EHT-0201
EHT-201
EHT0201
Flexital (TN)
Hemovas
IN1161
Ikomio
Oxpentifylline
P 1784
PENTOXYPHYLINE;PNX
PMID28870136-Compound-49
Pentox (TN)
Pentoxifilina
Pentoxifilina [INN-Spanish]
Pentoxifyllin
Pentoxifylline
Pentoxifylline (JAN/USP/INN)
Pentoxifylline [USAN:INN:JAN]
Pentoxifyllinum
Pentoxifyllinum [INN-Latin]
Pentoxil
Pentoxil (TN)
Pentoxin (TN)
Pentoxiphyllin
Pentoxiphylline
Pentoxiphyllium
Pentoxyfylline
Pentoxyphyllin
Pentoxyphylline
Ralofect
Rentylin
Torental
Trental (TN)
Trental;Vasofirin
Vazofirin
Show/Hide
|
||||||||||||||||||
Structure |
|
||||||||||||||||||
Formula |
C13H18N4O3
|
||||||||||||||||||
Molecular Weight |
278.312
|
||||||||||||||||||
Canonical SMILES |
CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O
Show/Hide
|
||||||||||||||||||
InChI |
InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
Show/Hide
|
||||||||||||||||||
InChIKey |
BYPFEZZEUUWMEJ-UHFFFAOYSA-N
|
||||||||||||||||||
CAS |
6493-05-6
|
||||||||||||||||||
Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
PubChem ID | |||||||||||||||||||
ChEMBL ID | |||||||||||||||||||
DrugBank ID |
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01305, 3',5'-cyclic-AMP phosphodiesterase 4B
Protein ID: PT01278, Adenosine receptor A2b
Clinical Information about the Compound
Drug 1 ( PMID28870136-Compound-49 )
Drug Name | PMID28870136-Compound-49 | ||
---|---|---|---|
Company | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC | ||
Target(s) |